3
Announcements
Trials
Browse
Landscape
Status
Recruiting
16
Active not recruiting
6
Not yet recruiting
4
Terminated
3
Withdrawn
2
Completed
2
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Approved for marketing
×
Triple Negative Breast Neoplasms
×
sacituzumab govitecan
×
Clear all
NCT04320693
2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing